Coud-Clone Corp.

APC150Hu01 100µg Active Collagen Type VI Alpha 1 (COL6a1) Organism Species: *Homo sapiens* (Human) *Instruction manual*

FOR RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

13th Edition (Revised in Aug, 2023)

[PROPERTIES]

Source: Prokaryotic expression. Host: *E. coli* Residues: Ala828~Ser1022 Tags: N-terminal His-tag Purity: >90% Endotoxin Level: <1.0EU per 1µg (determined by the LAL method). Buffer Formulation: PBS, pH7.4, containing 0.01% SKL, 5%Trehalose . Original Concentration: 200µg/mL Applications: Cell culture; Activity Assays. (May be suitable for use in other assays to be determined by the end user.) Predicted isoelectric point: 6.8 Predicted Molecular Mass: 22.5kDa Accurate Molecular Mass: 19kDa as determined by SDS-PAGE reducing conditions.

[<u>USAGE</u>]

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Cloud-Clone Corp.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[<u>SEQUENCE</u>]

ADI TILLDGSASV GSHNFDTTKR FAKRLAERFL TAGRTDPAHD VRVAVVQYSG TGQQRPERAS LQFLQNYTAL ASAVDAMDFI NDATDVNDAL GYVTRFYREA SSGAAKKRLL LFSDGNSQGA TPAAIEKAVQ EAQRAGIEIF VVVVGRQVNE PHIRVLVTGK TAEYDVAYGE SHLFRVPSYQ ALLRGVFHQT VS

[ACTIVITY]

Collagen alpha-1(VI) chain (COL6a1) is a protein that in humans, the collagens are a superfamily of proteins that play a role in maintaining the integrity of various tissues. Collagens are extracellular matrix proteins and have a triple-helical domain as their common structural element. Besides, Integrin Alpha V (ITGaV) has been identified as an interactor of COL6A1, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human COL6a1 and recombinant human ITGaV. Briefly, COL6a1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 ul were then transferred to ITGaV -coated microtiter wells and incubated for 2h at 37 °C. Wells were washed with PBST and incubated for 1h with anti-COL6a1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37 $^{\circ}$ C. Finally, add 50 µL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human COL6a1 and recombinant human ITGaV was shown in Figure 1, the EC50 for this effect is 0.19 ug/mL.

Cloud-Clone Corp.




Figure 1. The binding activity of recombinant human COL6a1 and recombinant human

ITGaV

[IDENTIFICATION]

kDa 70
44
 33 26 22
18
14
10

Figure 2. SDS-PAGE

Sample: Active recombinant COL6a1, Human

[IMPORTANT NOTE]

Cloud-Clone Corp.

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.